Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
Key facts
- Where
- Mexico City, MexicoSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06223074, who can take part
Where in Mexico
- Instituto Nacional de Neurologia y NeurocirugiaMexico City, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Nacional Autonoma de Mexico
- Trial code
- NCT06223074
- Record updated
- 3 April 2025
- Original description
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple SclerosisRead full original descriptionShow less
Towards the Improvement of the Treatment of Acute Relapses in Multiple Sclerosis: A Randomized Double-blind, Non-inferiority Controlled Trial Comparing Intranasal Versus Intravenous Methylprednisolone
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
Inclusion: Age between 18 and 65 years; Diagnosis of RRMS with an evolution from diagnosis of 3 months to 10 years; Kurtzke Expanded Disability Status Scale (EDSS) from 1 to 6 (grade 6 includes patients with unilateral aid to ambulate); No contraindication for the administration of MP; Agree to participate in the study by means of a signed informed consent.
Exclusion: Intake of anti-inflammatory steroids in the last 3 days; Patients with active bacterial, viral or fungal infections or undergoing treatment; Patients with hypertension; Patients with diabetes mellitus; Diagnosis of systemic diseases such as: cardiovascular, pulmonary, hepatic, endocrine, gastrointestinal, etc; Patients with a history of resistance to glucocorticoids; Patients with a history of severe adverse reactions to glucocorticoids; Patients with a history of hyposmia or anosmia; Patients with allergic rhinitis; Patients with upper respiratory tract infections; History of nasal surgery; Patients with suspected or confirmed pregnancy by means of serum or urinary laboratory tests; Patients with hypo or hyperthyroidism; Patients with glaucoma; Patients with neoplasms; Breastfeeding patients; Patients diagnosed with active sinusitis; deviated septum.